194 related articles for article (PubMed ID: 34694597)
1. Vosoritide: First Approval.
Duggan S
Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of vosoritide in the treatment of achondroplasia.
Paton DM
Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Chan ML; Qi Y; Larimore K; Cherukuri A; Seid L; Jayaram K; Jeha G; Fisheleva E; Day J; Huntsman-Labed A; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Horton WA; Henshaw J
Clin Pharmacokinet; 2022 Feb; 61(2):263-280. PubMed ID: 34431071
[TBL] [Abstract][Full Text] [Related]
4. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Savarirayan R; Tofts L; Irving M; Wilcox W; Bacino CA; Hoover-Fong J; Ullot Font R; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kagami S; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day J
Lancet; 2020 Sep; 396(10252):684-692. PubMed ID: 32891212
[TBL] [Abstract][Full Text] [Related]
5. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Savarirayan R; Irving M; Bacino CA; Bostwick B; Charrow J; Cormier-Daire V; Le Quan Sang KH; Dickson P; Harmatz P; Phillips J; Owen N; Cherukuri A; Jayaram K; Jeha GS; Larimore K; Chan ML; Huntsman Labed A; Day J; Hoover-Fong J
N Engl J Med; 2019 Jul; 381(1):25-35. PubMed ID: 31269546
[TBL] [Abstract][Full Text] [Related]
6. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Savarirayan R; Tofts L; Irving M; Wilcox WR; Bacino CA; Hoover-Fong J; Font RU; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kotani Y; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day JRS
Genet Med; 2021 Dec; 23(12):2443-2447. PubMed ID: 34341520
[TBL] [Abstract][Full Text] [Related]
7. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
8. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Savarirayan R; Wilcox WR; Harmatz P; Phillips J; Polgreen LE; Tofts L; Ozono K; Arundel P; Irving M; Bacino CA; Basel D; Bober MB; Charrow J; Mochizuki H; Kotani Y; Saal HM; Army C; Jeha G; Qi Y; Han L; Fisheleva E; Huntsman-Labed A; Day J
Lancet Child Adolesc Health; 2024 Jan; 8(1):40-50. PubMed ID: 37984383
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
Savarirayan R; Irving M; Maixner W; Thompson D; Offiah AC; Connolly DJ; Raghavan A; Powell J; Kronhardt M; Jeha G; Ghani S; Fisheleva E; Day JR
Sci Prog; 2021; 104(1):368504211003782. PubMed ID: 33761804
[TBL] [Abstract][Full Text] [Related]
10. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Wendt DJ; Dvorak-Ewell M; Bullens S; Lorget F; Bell SM; Peng J; Castillo S; Aoyagi-Scharber M; O'Neill CA; Krejci P; Wilcox WR; Rimoin DL; Bunting S
J Pharmacol Exp Ther; 2015 Apr; 353(1):132-49. PubMed ID: 25650377
[TBL] [Abstract][Full Text] [Related]
11. Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
Qi Y; Chan ML; Mould DR; Larimore K; Fisheleva E; Cherukuri A; Day J; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Bober MB; Henshaw J
Clin Pharmacokinet; 2024 May; 63(5):707-719. PubMed ID: 38649657
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
13. Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia.
Prickett TCR; Espiner EA; Irving M; Bacino C; Phillips JA; Savarirayan R; Day JRS; Fisheleva E; Larimore K; Chan ML; Jeha GS
Sci Rep; 2021 Dec; 11(1):24278. PubMed ID: 34930956
[TBL] [Abstract][Full Text] [Related]
14. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
Wrobel W; Pach E; Ben-Skowronek I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
[TBL] [Abstract][Full Text] [Related]
15. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
[TBL] [Abstract][Full Text] [Related]
16. [New treatments for achondroplasia may be efficacious in other forms of short stature].
Nilsson O
Lakartidningen; 2021 Feb; 118():. PubMed ID: 33647161
[TBL] [Abstract][Full Text] [Related]
17. Expanding horizons of achondroplasia treatment: current options and future developments.
Fafilek B; Bosakova M; Krejci P
Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
[TBL] [Abstract][Full Text] [Related]
18. A long-acting C-natriuretic peptide for achondroplasia.
Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
[TBL] [Abstract][Full Text] [Related]
19. Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.
Semler O; Cormier-Daire V; Lausch E; Bober MB; Carroll R; Sousa SB; Deyle D; Faden M; Hartmann G; Huser AJ; Legare JM; Mohnike K; Rohrer TR; Rutsch F; Smith P; Travessa AM; Verardo A; White KK; Wilcox WR; Hoover-Fong J
Adv Ther; 2024 Jan; 41(1):198-214. PubMed ID: 37882884
[TBL] [Abstract][Full Text] [Related]
20. Achondroplasia: pathogenesis and implications for future treatment.
Laederich MB; Horton WA
Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
